关注公众号
收藏产品 产品详情
抗体来源（Source）
Monoclonal Anti-NMTi Antibody, Rabbit IgG (M1E05) is a Rabbit monoclonal antibody recombinantly expressed from HEK293 cells.
克隆号（Clone）
M1E05
种属（Species）
Rabbit
亚型（Isotype）
Rabbit IgG | Rabbit Kappa
偶联（Conjugate）
Unconjugated
抗体类型（Antibody Type）
Recombinant Monoclonal
免疫原（Immunogen）
NMTi-BSA
特异性（Specificity）
Specifically recognizes NMTi.
应用（Application）
ApplicationRecommended UsageELISA0.5-250 ng/mL纯化（Purification）
Protein A purified / Protein G purified
制剂（Formulation）
Lyophilized from 0.22 μm filtered solution in PBS, pH7.4 with trehalose as protectant.
Contact us for customized product form or formulation.
重构方法（Reconstitution）
Please see Certificate of Analysis for specific instructions.
For best performance, we strongly recommend you to follow the reconstitution protocol provided in the CoA.
存储（Storage）
For long term storage, the product should be stored at lyophilized state at -20°C or lower.
Please avoid repeated freeze-thaw cycles.
This product is stable after storage at:
- -20°C to -70°C for 12 months in lyophilized state;
- -70°C for 3 months under sterile conditions after reconstitution.
质量管理控制体系（QMS）
推荐产品
数据展示
活性（Bioactivity）-ELISA
Immobilized Monoclonal Anti-NMTi Antibody, Rabbit IgG (M1E05) (Cat. No. NMI-MY2365) at 1 μg/mL (100 μL/well) can bind ADC-NMTi with a linear range of 0.5-16 ng/mL (QC tested).
Protocol
Serial dilutions of NMTi, N-Myristoyltransferase inhibitor were added into Monoclonal Anti-NMTi Antibody, Rabbit IgG (M1E05) (Cat. No. NMI-MY2365): ADC-NMTi binding reactions. The half maximal inhibitory concentration (IC50) is 1.27 μg/mL (Routinely tested).
Protocol
交叉验证-Cross Verification
ELISA binding of Monoclonal Anti-NMTi Antibody, Rabbit IgG (M1E05) (Cat. No. NMI-MY2365) with ADC-NMTi, Trastuzumab Deruxtecan, Sacituzumab Govitecam, Disitamab Vedotin (RC48), DM1 Antibody Human IgG and IgG1-MMAF conjugated antibody respectively.
The coating antibody was Monoclonal Anti-NMTi Antibody, Rabbit IgG (M1E05) (Cat. No. NMI-MY2365), used at 1 μg/mL concentration. The primary antibody were different payload conjugated antibodies, including ADC-NMTi, Trastuzumab Deruxtecan, Sacituzumab Govitecam, Disitamab Vedotin (RC48), DM1 Antibody Human IgG and IgG1-MMAF conjugated antibodies used at 0.5 μg/mL concentration. The secondary antibody was HRP conjugated Anti-Human-IgG-Fc Antibody (6F11C8), mAb (Acro, Cat. No. IGG-LY69) used at 1:10000 concentration.
Monoclonal Anti-NMTi Antibody, Rabbit IgG (M1E05) (Cat. No. NMI-MY2365) is specific to ADC-NMTi, and has no cross-reactivity with Trastuzumab Deruxtecan, Sacituzumab Govitecam, Disitamab Vedotin (RC48), DM1 Antibody Human IgG and IgG1-MMAF (Routinely tested).
用户评价 发表评论
联系我们 
项目合作 